CFN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. CareFusion Corp's research and development for the three months ended in Dec. 2013 was $47 Mil. Its research and development for the trailing twelve months (TTM) ended in Dec. 2013 was $192 Mil.
This is the expense the company spent on research and development.
CareFusion Corp Research & Development for the trailing twelve months (TTM) ended in Dec. 2013 was 47 (Mar. 2013 ) + 50 (Jun. 2013 ) + 48 (Sep. 2013 ) + 47 (Dec. 2013 ) = $192 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
CareFusion Corp Annual Data
|Research & Development||0||0||0||103||162||160||148||146||164||192|
CareFusion Corp Quarterly Data
|Research & Development||37||36||45||46||47||48||47||50||48||47|